The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

  1. Jimenez-Fonseca, P.
  2. Foy, V.
  3. Raby, S.
  4. Carmona-Bayonas, A.
  5. Macía-Rivas, L.
  6. Arrazubi, V.
  7. Cacho Lavin, D.
  8. Hernandez San Gil, R.
  9. Custodio, A.
  10. Cano, J.M.
  11. Fernández Montes, A.
  12. Mirallas, O.
  13. Macias Declara, I.
  14. Vidal Tocino, R.
  15. Visa, L.
  16. Limón, M.L.
  17. Pimentel, P.
  18. Martínez Lago, N.
  19. Sauri, T.
  20. Martín Richard, M.
  21. Mangas, M.
  22. Gil Raga, M.
  23. Calvo, A.
  24. Reguera, P.
  25. Granja, M.
  26. Martín Carnicero, A.
  27. Hernández Pérez, C.
  28. Cerdá, P.
  29. Gomez Gonzalez, L.
  30. Garcia Navalon, F.
  31. Pacheco Barcia, V.
  32. Gutierrez Abad, D.
  33. Ruiz Martín, M.
  34. Weaver, J.
  35. Mansoor, W.
  36. Gallego, J.
  37. Erakutsi egile guztiak +
Aldizkaria:
Therapeutic Advances in Medical Oncology

ISSN: 1758-8359,  1758-8340

Argitalpen urtea: 2023

Alea: 15

Mota: Artikulua

DOI: 10.1177/17588359231157641 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus